source
- FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High RiskFDA today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a rec…
- Boehringer targets 2027 submission of obesity drug survodutide after positive cardiovascular trialBoehringer Ingelheim announced that its experimental obesity therapy survodutide is moving toward regulatory filing. The move follows the drug's successful phase 3 cardiovascular outcomes study, w…Fierce Biotech · 4d agoPositive readoutPositive